Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for Eliquis ® (apixaban) and Sotyktu ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback